Logo

ESPR

Esperion Therapeutics, Inc.

ESPR

Esperion Therapeutics, Inc. • NASDAQ
$4.01 ▲ 1.52% (+0.06)
Market Cap $792.10 M
52w High $4.02
52w Low $0.69
Dividend Yield 0%
P/E -7.43
Volume 3.17M
Outstanding Shares 197.53M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $87.309M ▲ $41.848M ▼ $-31.333M ▼ -35.887% ▼ $-0.16 ▼ $-9.256M ▼
Q2-2025 $82.385M ▲ $46.747M ▼ $-12.725M ▲ -15.446% ▲ $-0.024 ▲ $7.788M ▲
Q1-2025 $64.995M ▼ $55.553M ▲ $-40.455M ▼ -62.243% ▼ $-0.21 ▼ $-20.998M ▼
Q4-2024 $69.113M ▲ $47.902M ▼ $-21.318M ▲ -30.845% ▲ $-0.11 ▲ $-4.869M ▲
Q3-2024 $51.632M $50.372M $-29.524M -57.182% $-0.15 $-14.416M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $92.447M ▲ $364.02M ▲ $815.381M ▲ $-451.361M ▼
Q2-2025 $86.061M ▼ $347.085M ▲ $780.594M ▲ $-433.509M ▼
Q1-2025 $114.633M ▼ $324.029M ▼ $750.24M ▲ $-426.211M ▼
Q4-2024 $144.761M ▲ $343.821M ▲ $732.543M ▲ $-388.722M ▼
Q3-2024 $144.717M $314.114M $684.323M $-370.209M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-31.333M ▼ $-4.286M ▲ $0 $10.672M ▲ $6.386M ▲ $-4.286M ▲
Q2-2025 $-12.725M ▲ $-31.422M ▼ $0 $2.85M ▲ $-28.572M ▲ $-31.422M ▼
Q1-2025 $-40.455M ▼ $-22.628M ▲ $0 $-7.5M ▼ $-30.128M ▼ $-22.628M ▲
Q4-2024 $-21.318M ▲ $-34.952M ▲ $0 ▲ $34.996M ▲ $44K ▲ $-34.952M ▲
Q3-2024 $-29.524M $-35.325M $-167K $-9.095M $-44.587M $-35.492M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Collaboration Revenue
Collaboration Revenue
 $80.00M ▲$30.00M ▼$40.00M ▲$50.00M ▲
Product
Product
 $60.00M ▲$30.00M ▼$40.00M ▲$40.00M ▲

Five-Year Company Overview

Income Statement

Income Statement Esperion has moved from heavy losses toward something much closer to break‑even at the operating level. Sales have grown meaningfully over the last few years, and the business has shifted from sizeable operating losses to a small operating profit and roughly breakeven earnings before non‑cash items. However, after interest and other costs, the company is still losing money overall. The direction of travel is positive—better revenue, better margins, smaller losses—but profitability is not yet firmly established and remains sensitive to any setback in sales growth or expenses.

Balance Sheet

Balance Sheet The balance sheet is a mixed picture. On the positive side, the company still holds a meaningful cash cushion relative to its size, and total assets have grown in recent years. On the risk side, debt levels are now quite high compared with the asset base, and accounting equity remains deeply negative. That combination points to a leveraged and financially fragile structure: the business depends on continued access to funding and on further improvement in earnings to strengthen its financial footing over time.

Cash Flow

Cash Flow Cash flow from operations has improved dramatically—from sizable cash burn a few years ago to only modest outflows recently. Capital spending is very light, so free cash flow closely tracks operating cash flow and is also near breakeven but still slightly negative. This suggests the core products are moving closer to self‑funding, yet the company is not fully cash‑generative and may still need external capital if growth or R&D spending increases or if sales underperform.

Competitive Edge

Competitive Edge Esperion operates in a tough, highly regulated cardiovascular market, but it has carved out a differentiated niche. Its flagship bempedoic acid products are oral, non‑statin cholesterol‑lowering drugs aimed particularly at patients who cannot tolerate statins or need more help on top of them. Strong clinical results from a large outcomes trial and a broadened U.S. label enhance credibility with doctors and payers. A long runway of patent protection and settlements with potential generic rivals provide legal protection into the next decade. The flip side is that Esperion still competes with powerful incumbents, including both generic statins and newer injectable therapies, so execution in marketing, reimbursement, and global partnerships will be critical.

Innovation and R&D

Innovation and R&D The company’s R&D strategy is focused and ambitious. It has built deep expertise around ACL/ACLY biology and is extending that know‑how into “next‑gen” inhibitors that could be more potent or applicable well beyond cholesterol, including in liver disease, metabolic disorders, kidney disease, and potentially cancer. Today, most of this pipeline is at an early, preclinical stage, which means long timelines and high scientific and regulatory uncertainty. Still, the combination of a validated first product platform and a clearly articulated next wave of candidates suggests an innovation engine rather than a one‑drug story.

Summary

Esperion is in transition from a development‑stage biotech toward a commercial specialty pharma company. Revenue growth and margin improvement show that its cholesterol‑lowering products are gaining traction, and operating performance has improved markedly, though the company remains unprofitable and modestly cash‑burning. A heavy debt load and negative equity represent key financial risks that increase the importance of sustaining product momentum and controlling costs. On the strategic side, Esperion benefits from a differentiated, oral non‑statin offering with strong clinical data and long patent protection, giving it a credible competitive niche in cardiovascular care. Its early‑stage pipeline aims to broaden the company into multiple disease areas, but that upside is uncertain and will take years to play out. Overall, the story is one of improving fundamentals, meaningful scientific assets, and clear but significant financial and execution risks.

NEWS

November 18, 2025 · 7:00 AM UTC

Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease

Read more

November 6, 2025 · 4:30 PM UTC

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Read more

November 4, 2025 · 8:00 AM UTC

Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer

Read more

October 27, 2025 · 8:00 AM UTC

Esperion Announces New Analyses from CLEAR Outcomes to be Presented at the American Heart Association (AHA) Scientific Sessions 2025

Read more

October 7, 2025 · 9:29 PM UTC

Esperion Announces Pricing of Public Offering of Common Stock

Read more